Results 61 to 70 of about 48,845 (222)

Sunitinib-induced hand-foot syndrome in a Kashmiri male

open access: yes, 2016
Sunitinib belongs to multiple tyrosine kinase inhibitor class of novel targeted therapies used for metastatic solid tumours including renal cell carcinoma.
Parvaiz A Rather   +2 more
core   +1 more source

Fluvastatin enhances the sensitivity of clear cell renal cell carcinoma to sunitinib by inhibiting PHF8

open access: yes陆军军医大学学报
Objective Sunitinib resistance is an important factor affecting the efficacy of targeted therapy for clear cell renal cell carcinoma (ccRCC), and its underlying molecular mechanisms and effective intervention strategies have not been fully elucidated ...
Wang Ziqian   +3 more
doaj   +1 more source

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence

open access: yesTherapeutic Advances in Urology, 2017
Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects, although an indirect inhibitory effect on tumor growth and, more recently, a complex activity on antitumor immune response has been described. From approval by
Mimma Rizzo, Camillo Porta
doaj   +1 more source

Green Tea Extract Decreases the Systemic Exposure of Pazopanib in Healthy Participants

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Green tea catechins modulate the activity of key drug pharmacokinetic determinants and consequently, concomitant consumption of green tea can significantly alter systemic drug exposure. This study aimed to investigate the influence of concomitant green tea catechin consumption on the pharmacokinetics of pazopanib, a tyrosine kinase inhibitor used in ...
Nicki M. Kyriacou   +4 more
wiley   +1 more source

Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC

open access: yesNeoplasia: An International Journal for Oncology Research, 2015
Anti-angiogenic treatment with tyrosine kinase inhibitors (TKI) has lead to an impressive increase in progression-free survival for patients with metastatic RCC (mRCC), but mRCC remains largely incurable.
Jeannette C. Oosterwijk-Wakka   +7 more
doaj   +1 more source

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo   +10 more
wiley   +1 more source

Inhibition of Autophagy Enhances Sunitinib-Induced Cytotoxicity in Rat Pheochromocytoma PC12 cells

open access: yesJournal of Pharmacological Sciences, 2013
Sunitinib is an oral multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity that mainly targets vascular endothelial growth factor receptors, and recently, it has been shown to be an active agent for the treatment of ...
Tatsuhiko Ikeda   +8 more
doaj   +1 more source

Composite Inflammatory Score for Predicting Progression‐Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First‐Line Toripalimab Plus Axitinib

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Routine inflammatory and nutritional markers may help stratify progression risk in metastatic clear cell renal cell carcinoma during immunotherapy‐based treatment. This single‐center retrospective study included 237 patients who received first‐line toripalimab plus axitinib therapy.
Yun‐Feng Wu   +4 more
wiley   +1 more source

The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA.

open access: yesPLoS ONE, 2012
Constitutive activation of pro-survival kinases has become a promising target of small molecules with an increasing interest in developing multi-targeted agents.
Jing Sun   +8 more
doaj   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

open access: yesMass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy